{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:43:11Z","timestamp":1792190591748,"version":"4.4.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40265-025-02233-6","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T14:01:55Z","timestamp":1756476115000},"page":"1381-1390","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Systemic Therapy for Advanced Thyroid Cancer\u2014New Personalized Options"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3981-897X","authenticated-orcid":false,"given":"Leslie","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Newbold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"2233_CR1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1210\/ER.2001-0029","volume":"24","author":"O Doh\u00e1n","year":"2003","unstructured":"Doh\u00e1n O, De La Vieja A, Paroder V, Riedel C, Artani M, Reed M, et al. The sodium\/iodide symporter (NIS): characterization, regulation, and medical significance. Endocr Rev. 2003;24:48\u201377. https:\/\/doi.org\/10.1210\/ER.2001-0029.","journal-title":"Endocr Rev"},{"key":"2233_CR2","first-page":"5888","volume":"11","author":"B Lin","year":"2019","unstructured":"Lin B, Ma H, Ma M, Zhang Z, Sun Z, Hsieh IY, et al. The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis. Am J Transl Res. 2019;11:5888.","journal-title":"Am J Transl Res"},{"key":"2233_CR3","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23986","author":"C Romei","year":"2018","unstructured":"Romei C, Ciampi R, Casella F, Tacito A, Torregrossa L, Ugolini C, et al. RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases. Oncotarget. 2018. https:\/\/doi.org\/10.18632\/oncotarget.23986.","journal-title":"Oncotarget"},{"key":"2233_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/J.EJSO.2004.11.002","volume":"31","author":"SL Hyer","year":"2005","unstructured":"Hyer SL, Newbold K, Harmer C. Familial medullary thyroid cancer: clinical aspects and prognosis. Eur J Surg Oncol (EJSO). 2005;31:415\u20139. https:\/\/doi.org\/10.1016\/J.EJSO.2004.11.002.","journal-title":"Eur J Surg Oncol (EJSO)"},{"key":"2233_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0030-6665(02)00136-6","volume":"36","author":"GL Clayman","year":"2003","unstructured":"Clayman GL, El-Baradie TS. Medullary thyroid cancer. Otolaryngol Clin N Am. 2003;36:91\u2013105. https:\/\/doi.org\/10.1016\/S0030-6665(02)00136-6.","journal-title":"Otolaryngol Clin N Am"},{"key":"2233_CR6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic diff erentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384:319\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(14)60421-9.","journal-title":"Lancet"},{"key":"2233_CR7","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1406470.","journal-title":"N Engl J Med"},{"key":"2233_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12020-017-1233-5","volume":"56","author":"RI Haddad","year":"2017","unstructured":"Haddad RI, Schlumberger M, Wirth LJ, Sherman EJ, Shah MH, Robinson B, et al. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine. 2017;56:121\u20138. https:\/\/doi.org\/10.1007\/s12020-017-1233-5.","journal-title":"Endocrine"},{"key":"2233_CR9","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3892\/MCO.2019.1964","volume":"12","author":"H Iwasaki","year":"2019","unstructured":"Iwasaki H, Toda S, Suganuma N, Murayama D, Nakayama H, Masudo K. Lenvatinib vs. palliative therapy for stage IVC anaplastic thyroid cancer. Mol Clin Oncol. 2019;12:138. https:\/\/doi.org\/10.3892\/MCO.2019.1964.","journal-title":"Mol Clin Oncol"},{"key":"2233_CR10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2217\/FON-2018-0557","volume":"15","author":"S Takahashi","year":"2019","unstructured":"Takahashi S, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, et al. A phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncol. 2019;15:717\u201326. https:\/\/doi.org\/10.2217\/FON-2018-0557.","journal-title":"Future Oncol"},{"key":"2233_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1530\/ERC-20-0106","volume":"28","author":"C Sparano","year":"2021","unstructured":"Sparano C, Godbert Y, Attard M, Do Cao C, Zerdoud S, Roudaut N, et al. Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview. Endocr Relat Cancer. 2021;28:15\u201326. https:\/\/doi.org\/10.1530\/ERC-20-0106.","journal-title":"Endocr Relat Cancer"},{"key":"2233_CR12","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S1470-2045(21)00332-6","volume":"22","author":"MS Brose","year":"2021","unstructured":"Brose MS, Robinson B, Sherman SI, Krajewska J, Lin CC, Vaisman F, et al. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22:1126\u201338. https:\/\/doi.org\/10.1016\/S1470-2045(21)00332-6.","journal-title":"Lancet Oncol"},{"key":"2233_CR13","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1002\/cncr.34493","volume":"128","author":"MS Brose","year":"2022","unstructured":"Brose MS, Robinson BG, Sherman SI, Jarzab B, Lin CC, Vaisman F, et al. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: updated results from the phase 3 COSMIC-311 trial. Cancer. 2022;128:4203\u201312. https:\/\/doi.org\/10.1002\/cncr.34493.","journal-title":"Cancer"},{"key":"2233_CR14","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","volume":"31","author":"R Elisei","year":"2013","unstructured":"Elisei R, Schlumberger MJ, M\u00fcller SP, Sch\u00f6ffski P, Brose MS, Shah MH, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31:3639. https:\/\/doi.org\/10.1200\/JCO.2012.48.4659.","journal-title":"J Clin Oncol"},{"key":"2233_CR15","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1093\/annonc\/mdx479","volume":"28","author":"M Schlumberger","year":"2017","unstructured":"Schlumberger M, Elisei R, M\u00fcller S, Sch\u00f6ffski P, Brose M, Shah M, et al. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann Oncol. 2017;28:2813\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdx479.","journal-title":"Ann Oncol"},{"key":"2233_CR16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","volume":"30","author":"SA Wells","year":"2012","unstructured":"Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30:134. https:\/\/doi.org\/10.1200\/JCO.2011.35.5040.","journal-title":"J Clin Oncol"},{"key":"2233_CR17","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1200\/JCO.19.02790\/ASSET\/7044EF75-3DDA-40ED-B88C-C75FD6A71D9C\/ASSETS\/IMAGES\/LARGE\/JCO.19.02790TA2.JPG","volume":"38","author":"MC Kreissl","year":"2020","unstructured":"Kreissl MC, Bastholt L, Elisei R, Haddad R, Hauch O, Jarzab B, et al. Efficacy and safety of vandetanib in progressive and symptomatic medullary thyroid cancer: post hoc analysis from the ZETA trial. J Clin Oncol. 2020;38:2773\u201381. https:\/\/doi.org\/10.1200\/JCO.19.02790\/ASSET\/7044EF75-3DDA-40ED-B88C-C75FD6A71D9C\/ASSETS\/IMAGES\/LARGE\/JCO.19.02790TA2.JPG.","journal-title":"J Clin Oncol"},{"key":"2233_CR18","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/nejmoa2005651","volume":"383","author":"LJ Wirth","year":"2020","unstructured":"Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020;383:825\u201335. https:\/\/doi.org\/10.1056\/nejmoa2005651.","journal-title":"N Engl J Med"},{"key":"2233_CR19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02503\/SUPPL_FILE\/PROTOCOL_JCO.23.02503.PDF","author":"LJ Wirth","year":"2024","unstructured":"Wirth LJ, Brose MS, Subbiah V, Worden F, Solomon B, Robinson B, et al. Durability of response with selpercatinib in patients with RET-activated thyroid cancer: long-term safety and efficacy from LIBRETTO-001. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.23.02503\/SUPPL_FILE\/PROTOCOL_JCO.23.02503.PDF.","journal-title":"J Clin Oncol"},{"key":"2233_CR20","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","volume":"389","author":"J Hadoux","year":"2023","unstructured":"Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, et al. Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer. N Engl J Med. 2023;389:1851\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2309719.","journal-title":"N Engl J Med"},{"key":"2233_CR21","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00096\/ASSET\/755AF2F3-BA07-463B-AE47-8ED9D7EEECB1\/ASSETS\/IMAGES\/LARGE\/PO.20.00096F2.JPG","author":"A Andreev-Drakhlin","year":"2020","unstructured":"Andreev-Drakhlin A, Cabanillas M, Amini B, Subbiah V. Systemic and CNS activity of selective RET inhibition with selpercatinib (LOXO-292) in a patient with RET-mutant medullary thyroid cancer with extensive CNS metastases. JCO Precis Oncol. 2020. https:\/\/doi.org\/10.1200\/PO.20.00096\/ASSET\/755AF2F3-BA07-463B-AE47-8ED9D7EEECB1\/ASSETS\/IMAGES\/LARGE\/PO.20.00096F2.JPG.","journal-title":"JCO Precis Oncol"},{"key":"2233_CR22","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","volume":"9","author":"V Subbiah","year":"2021","unstructured":"Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study. Lancet Diabetes Endocrinol. 2021;9:491\u2013501. https:\/\/doi.org\/10.1016\/S2213-8587(21)00120-0.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2233_CR23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/J.ANNONC.2020.10.599","volume":"32","author":"V Subbiah","year":"2021","unstructured":"Subbiah V, Shen T, Terzyan SS, Liu X, Hu X, Patel KP, et al. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol. 2021;32(2):261\u20138. https:\/\/doi.org\/10.1016\/J.ANNONC.2020.10.599.","journal-title":"Ann Oncol"},{"key":"2233_CR24","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/J.JTHO.2020.01.006","volume":"15","author":"BJ Solomon","year":"2020","unstructured":"Solomon BJ, Tan L, Lin JJ, Wong SQ, Hollizeck S, Ebata K, et al. RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies. J Thorac Oncol. 2020;15:541. https:\/\/doi.org\/10.1016\/J.JTHO.2020.01.006.","journal-title":"J Thorac Oncol"},{"key":"2233_CR25","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1200\/JCO.22.01644\/ASSET\/BFBEB42E-1223-4682-A1D1-C3F88389F8E0\/ASSETS\/IMAGES\/LARGE\/JCO.22.01644F1.JPG","volume":"41","author":"JJ Lin","year":"2023","unstructured":"Lin JJ, Gainor JF. Selective targeting of RET fusions in lung cancer. J Clin Oncol. 2023;41:410\u20132. https:\/\/doi.org\/10.1200\/JCO.22.01644\/ASSET\/BFBEB42E-1223-4682-A1D1-C3F88389F8E0\/ASSETS\/IMAGES\/LARGE\/JCO.22.01644F1.JPG.","journal-title":"J Clin Oncol"},{"key":"2233_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-28848-x","volume":"13","author":"EY Rosen","year":"2022","unstructured":"Rosen EY, Won HH, Zheng Y, Cocco E, Selcuklu D, Gong Y, et al. The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. Nat Commun. 2022;13:1\u20139. https:\/\/doi.org\/10.1038\/s41467-022-28848-x.","journal-title":"Nat Commun"},{"key":"2233_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/CAM4.7351","volume":"13","author":"E Nakata","year":"2024","unstructured":"Nakata E, Osone T, Ogawa T, Taguchi T, Hattori K, Kohsaka S. Prevalence of neurotrophic tropomyosin receptor kinase (NTRK) fusion gene positivity in patients with solid tumors in Japan. Cancer Med. 2024;13: e7351. https:\/\/doi.org\/10.1002\/CAM4.7351.","journal-title":"Cancer Med"},{"key":"2233_CR28","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00442","volume":"6","author":"JC Park","year":"2022","unstructured":"Park JC, Ashok A, Liu C, Kang H. Real-world experience of NTRK fusion-positive thyroid cancer. JCO Precis Oncol. 2022;6: e2100442. https:\/\/doi.org\/10.1200\/PO.21.00442.","journal-title":"JCO Precis Oncol"},{"key":"2233_CR29","doi-asserted-by":"publisher","first-page":"R43","DOI":"10.1530\/joe-17-0266","volume":"235","author":"MA Zaballos","year":"2017","unstructured":"Zaballos MA, Santisteban P. Key signaling pathways in thyroid cancer. J Endocrinol. 2017;235:R43-61. https:\/\/doi.org\/10.1530\/joe-17-0266.","journal-title":"J Endocrinol"},{"key":"2233_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/ANNONC\/MDZ383","volume":"30","author":"A Amatu","year":"2019","unstructured":"Amatu A, Sartore-Bianchi A, Bencardino K, Pizzutilo EG, Tosi F, Siena S. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. Ann Oncol. 2019;30: viii5. https:\/\/doi.org\/10.1093\/ANNONC\/MDZ383.","journal-title":"Ann Oncol"},{"issue":"8","key":"2233_CR31","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMOA1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion\u2013positive cancers in adults and children. N Engl J Med. 2018;378(8):731\u20139. https:\/\/doi.org\/10.1056\/NEJMOA1714448.","journal-title":"N Engl J Med"},{"key":"2233_CR32","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1530\/EJE-21-1259","volume":"186","author":"SG Waguespack","year":"2022","unstructured":"Waguespack SG, Drilon A, Lin JJ, Brose MS, McDermott R, Almubarak M, et al. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol. 2022;186:631\u201343. https:\/\/doi.org\/10.1530\/EJE-21-1259.","journal-title":"Eur J Endocrinol"},{"key":"2233_CR33","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"21","author":"DS Hong","year":"2020","unstructured":"Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol. 2020;21:531\u201340. https:\/\/doi.org\/10.1016\/S1470-2045(19)30856-3.","journal-title":"Lancet Oncol"},{"key":"2233_CR34","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"RC Doebele","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials. Lancet Oncol. 2020;21:271\u201382. https:\/\/doi.org\/10.1016\/S1470-2045(19)30691-6.","journal-title":"Lancet Oncol"},{"key":"2233_CR35","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597\/677957\/AM\/UPDATED-INTEGRATED-ANALYSIS-OF-THE-EFFICACY-AND","volume":"28","author":"GD Demetri","year":"2022","unstructured":"Demetri GD, De Braud F, Drilon A, Siena S, Patel MR, Cho BC, et al. Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors. Clin Cancer Res. 2022;28:1302\u201312. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3597\/677957\/AM\/UPDATED-INTEGRATED-ANALYSIS-OF-THE-EFFICACY-AND.","journal-title":"Clin Cancer Res"},{"key":"2233_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","volume":"36","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Cabanillas ME, Kreitman RJ, Wainberg ZA, Cho JY, Keam B, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600\u2013mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36:7. https:\/\/doi.org\/10.1200\/JCO.2017.73.6785.","journal-title":"J Clin Oncol"},{"key":"2233_CR37","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022;33:406\u201315. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.014.","journal-title":"Ann Oncol"},{"key":"2233_CR38","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","volume":"29","author":"V Subbiah","year":"2023","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, Gazzah A, Lassen U, Stein A, et al. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med. 2023;29:1103\u201312. https:\/\/doi.org\/10.1038\/s41591-023-02321-8.","journal-title":"Nat Med"},{"key":"2233_CR39","doi-asserted-by":"publisher","first-page":"6022","DOI":"10.1200\/JCO.2017.35.15_SUPPL.6022","volume":"35","author":"MH Shah","year":"2017","unstructured":"Shah MH, Wei L, Wirth LJ, Daniels GA, De SJA, Timmers CD, et al. Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma. J Clin Oncol. 2017;35:6022\u20136022. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_SUPPL.6022.","journal-title":"J Clin Oncol"},{"key":"2233_CR40","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1089\/THY.2022.0115","volume":"32","author":"NL Busaidy","year":"2022","unstructured":"Busaidy NL, Konda B, Wei L, Wirth LJ, Devine C, Daniels GA, et al. Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial. Thyroid. 2022;32:1184. https:\/\/doi.org\/10.1089\/THY.2022.0115.","journal-title":"Thyroid"},{"key":"2233_CR41","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/S41591-023-02379-4","volume":"29","author":"PJ O\u2019Dwyer","year":"2023","unstructured":"O\u2019Dwyer PJ, Gray RJ, Flaherty KT, Chen AP, Li S, Wang V, et al. The NCI-MATCH trial: lessons for precision oncology. Nat Med. 2023;29:1349\u201357. https:\/\/doi.org\/10.1038\/S41591-023-02379-4.","journal-title":"Nat Med"},{"key":"2233_CR42","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/S10147-024-02562-8","volume":"29","author":"N Matsumura","year":"2024","unstructured":"Matsumura N, Mandai M. PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of pembrolizumab for gastric and biliary tract cancer and encorafenib and binimetinib for thyroid cancer in Japan. Int J Clin Oncol. 2024;29:1053\u20134. https:\/\/doi.org\/10.1007\/S10147-024-02562-8.","journal-title":"Int J Clin Oncol"},{"key":"2233_CR43","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/S12885-019-5380-3","volume":"19","author":"JM Mehnert","year":"2019","unstructured":"Mehnert JM, Varga A, Brose MS, Aggarwal RR, Lin CC, Prawira A, et al. Safety and antitumor activity of the anti\u2013PD-1 antibody pembrolizumab in patients with advanced, PD-L1\u2013positive papillary or follicular thyroid cancer. BMC Cancer. 2019;19:196. https:\/\/doi.org\/10.1186\/S12885-019-5380-3.","journal-title":"BMC Cancer"},{"key":"2233_CR44","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1001\/JAMAONCOL.2024.4019","volume":"10","author":"K Sehgal","year":"2024","unstructured":"Sehgal K, Pappa T, Shin K-Y, Schiantarelli J, Liu M, Ricker C, et al. Dual immune checkpoint inhibition in patients with aggressive thyroid carcinoma: a phase 2 nonrandomized clinical trial. JAMA Oncol. 2024;10:1663\u201371. https:\/\/doi.org\/10.1001\/JAMAONCOL.2024.4019.","journal-title":"JAMA Oncol"},{"key":"2233_CR45","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12020-019-01865-5","volume":"64","author":"S Cantara","year":"2019","unstructured":"Cantara S, Bertelli E, Occhini R, Regoli M, Brilli L, Pacini F, et al. Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer. Endocrine. 2019;64:122\u20139. https:\/\/doi.org\/10.1007\/s12020-019-01865-5.","journal-title":"Endocrine"},{"key":"2233_CR46","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1210\/jc.2016-3756","volume":"102","author":"AV Chintakuntlawar","year":"2017","unstructured":"Chintakuntlawar AV, Rumilla KM, Smith CY, Jenkins SM, Foote RL, Kasperbauer JL, et al. Expression of PD-1 and PD-L1 in anaplastic thyroid cancer patients treated with multimodal therapy: results from a retrospective study. J Clin Endocrinol Metab. 2017;102:1943\u201350. https:\/\/doi.org\/10.1210\/jc.2016-3756.","journal-title":"J Clin Endocrinol Metab"},{"key":"2233_CR47","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214\u20138. https:\/\/doi.org\/10.1038\/nature12213.","journal-title":"Nature"},{"key":"2233_CR48","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1200\/JCO.19.02727","volume":"38","author":"J Capdevila","year":"2020","unstructured":"Capdevila J, Wirth LJ, Ernst T, Aix SP, Lin CC, Ramlau R, et al. PD-1 blockade in anaplastic thyroid carcinoma. J Clin Oncol. 2020;38:2620. https:\/\/doi.org\/10.1200\/JCO.19.02727.","journal-title":"J Clin Oncol"},{"key":"2233_CR49","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1089\/thy.2020.0322","volume":"31","author":"C Dierks","year":"2021","unstructured":"Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, et al. Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid. 2021;31:1076\u201385. https:\/\/doi.org\/10.1089\/thy.2020.0322.","journal-title":"Thyroid"},{"key":"2233_CR50","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1001\/JAMAONCOL.2024.4729","volume":"10","author":"ME Cabanillas","year":"2024","unstructured":"Cabanillas ME, Dadu R, Ferrarotto R, Gule-Monroe M, Liu S, Fellman B, et al. Anti\u2013programmed death ligand 1 plus targeted therapy in anaplastic thyroid carcinoma: a nonrandomized clinical trial. JAMA Oncol. 2024;10:1672. https:\/\/doi.org\/10.1001\/JAMAONCOL.2024.4729.","journal-title":"JAMA Oncol"},{"key":"2233_CR51","unstructured":"Study Details | Lenvatinib and pembrolizumab for the treatment of stage IVB locally advanced and unresectable or stage IVC metastatic anaplastic thyroid cancer | ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/study\/NCT04171622. Accessed 15 Mar 2025."},{"key":"2233_CR52","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1089\/THY.2023.0573","volume":"34","author":"S Hamidi","year":"2024","unstructured":"Hamidi S, Iyer PC, Dadu R, Gule-Monroe MK, Maniakas A, Zafereo ME, et al. Checkpoint inhibition in addition to dabrafenib\/trametinib for BRAFV600E-mutated anaplastic thyroid carcinoma. Thyroid\u00ae. 2024;34:336\u201346. https:\/\/doi.org\/10.1089\/THY.2023.0573.","journal-title":"Thyroid\u00ae"},{"key":"2233_CR53","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1056\/NEJMOA1209288","volume":"368","author":"AL Ho","year":"2013","unstructured":"Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013;368:623\u201332. https:\/\/doi.org\/10.1056\/NEJMOA1209288.","journal-title":"N Engl J Med"},{"key":"2233_CR54","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1089\/THY.2022.0707","volume":"33","author":"J Wadsley","year":"2023","unstructured":"Wadsley J, Ainsworth G, Coulson AB, Garcez K, Moss L, Newbold K, et al. Results of the SEL-I-METRY phase II trial on resensitization of advanced iodine refractory differentiated thyroid cancer to radioiodine therapy. Thyroid. 2023;33:1119. https:\/\/doi.org\/10.1089\/THY.2022.0707.","journal-title":"Thyroid"},{"key":"2233_CR55","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1158\/1078-0432.CCR-23-0046\/726018\/AM\/A-PHASE-II-REDIFFERENTIATION-TRIAL-WITH-DABRAFENIB","volume":"29","author":"S Leboulleux","year":"2023","unstructured":"Leboulleux S, Do Cao C, Zerdoud S, Attard M, Bournaud C, Lacroix L, et al. A phase II redifferentiation trial with dabrafenib-trametinib and 131I in metastatic radioactive iodine refractory BRAF p.V600E-mutated differentiated thyroid cancer. Clin Cancer Res. 2023;29:2401\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0046\/726018\/AM\/A-PHASE-II-REDIFFERENTIATION-TRIAL-WITH-DABRAFENIB.","journal-title":"Clin Cancer Res"},{"key":"2233_CR56","unstructured":"Study Details | A study of avutometinib and defactinib in people with thyroid cancer | ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/study\/NCT06007924. Accessed 31 July 2025."},{"key":"2233_CR57","doi-asserted-by":"publisher","first-page":"1411300","DOI":"10.3389\/FIMMU.2024.1411300\/BIBTEX","volume":"15","author":"Z Sun","year":"2024","unstructured":"Sun Z, Wang C, Zhao Y, Ling Q. CAR-T cell therapy in advanced thyroid cancer: from basic to clinical. Front Immunol. 2024;15:1411300. https:\/\/doi.org\/10.3389\/FIMMU.2024.1411300\/BIBTEX.","journal-title":"Front Immunol"},{"key":"2233_CR58","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1210\/CLINEM\/DGAB819","volume":"107","author":"H Li","year":"2022","unstructured":"Li H, Zhou X, Wang G, Hua D, Li S, Xu T, et al. CAR-T cells targeting TSHR demonstrate safety and potent preclinical activity against differentiated thyroid cancer. J Clin Endocrinol Metab. 2022;107:1110\u201326. https:\/\/doi.org\/10.1210\/CLINEM\/DGAB819.","journal-title":"J Clin Endocrinol Metab"},{"key":"2233_CR59","doi-asserted-by":"publisher","first-page":"6095","DOI":"10.1200\/JCO.2023.41.16_SUPPL.6095","volume":"41","author":"SA Srour","year":"2023","unstructured":"Srour SA, Cabanillas ME, Gupta S, Zafereo ME, Lu Y, Dadu R, et al. Safety and early efficacy results of phase 1 study of affinity tuned and trackable AIC100 CAR T cells in ICAM-1 positive relapsed and\/or refractory advanced poorly differentiated and anaplastic thyroid cancers. J Clin Oncol. 2023;41:6095\u20136095. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_SUPPL.6095.","journal-title":"J Clin Oncol"},{"key":"2233_CR60","doi-asserted-by":"publisher","first-page":"6093","DOI":"10.1200\/JCO.2022.40.16_SUPPL.6093","volume":"40","author":"JM Hsu","year":"2022","unstructured":"Hsu JM, von Hofe E, Hsu Y-M, Shieh J-H, Chaekal O-K, Guarneri D, et al. Phase I study of AIC100 in relapsed and\/or refractory advanced thyroid cancer and anaplastic thyroid cancer. J Clin Oncol. 2022;40:6093\u20136093. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_SUPPL.6093.","journal-title":"J Clin Oncol"},{"key":"2233_CR61","doi-asserted-by":"publisher","first-page":"1213716","DOI":"10.3389\/FIMMU.2023.1213716","volume":"14","author":"C Hu","year":"2023","unstructured":"Hu C, Liu M, Li Y, Zhao Y, Sharma A, Liu H, et al. Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer. Front Immunol. 2023;14:1213716. https:\/\/doi.org\/10.3389\/FIMMU.2023.1213716.","journal-title":"Front Immunol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02233-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02233-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02233-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:31:17Z","timestamp":1761715877000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02233-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":61,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2233"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02233-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Leslie Cheng and Kate Newbold declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"No datasets were generated or analysed during the current study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"L.C. was responsible for literature review, manuscript drafting and design. K.N. was responsible for defining the scope of the manuscript, editing and critical revisions. Both authors have approved the final version of this manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}